Cargando…
ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
PURPOSE: Discontinuation of denosumab (DMab) is associated with rapid declinein bone density. Sequential antiresorptive drugs are recommended to preserve bone mass after DMab treatment. It remains unclear whether raloxifene exclusively can be used in certain conditions to attenuate bone loss after D...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624547/ http://dx.doi.org/10.1210/jendso/bvac150.361 |